Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Myovant Sciences Ltd. MYOV
$26.98
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
2624061418.00000000
-
week52high
27.06
-
week52low
7.67
-
Revenue
230972000
-
P/E TTM
-14
-
Beta
2.15468200
-
EPS
-1.92000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Market Perform | 09 авг 2022 г. |
| Goldman Sachs | Neutral | Neutral | 28 июл 2022 г. |
| Goldman Sachs | Neutral | Neutral | 11 мая 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 13 апр 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 16 февр 2022 г. |
| Evercore ISI Group | In-Line | Outperform | 26 окт 2022 г. |
| SVB Leerink | Market Perform | Outperform | 25 окт 2022 г. |
| Baird | Neutral | Outperform | 24 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lang Matthew | D | 354303 | 1272 | 18 янв 2023 г. |
| Arjona Ferreira Juan Camilo | D | 246684 | 1109 | 18 янв 2023 г. |
| Marek David C | D | 417599 | 8037 | 18 янв 2023 г. |
| Merendino Lauren | D | 169538 | 2008 | 18 янв 2023 г. |
| Lang Matthew | D | 355575 | 2779 | 04 янв 2023 г. |
| Arjona Ferreira Juan Camilo | D | 247793 | 2251 | 04 янв 2023 г. |
| Mehra Uneek | D | 202696 | 2241 | 16 дек 2022 г. |
| Curran Terrie | A | 9859 | 9859 | 26 окт 2022 г. |
| GUINAN MARK | A | 9859 | 9859 | 26 окт 2022 г. |
| POTTER MYRTLE S | A | 9859 | 9859 | 26 окт 2022 г. |
Новостная лента
Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
26 янв 2023 г. в 18:48
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
26 окт 2022 г. в 11:19
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Sumitomo Pharma Is Buying Myovant Sciences (MYOV) For $2.9 Billion
Pulse2
24 окт 2022 г. в 23:29
Sumitovant Biopharma recently announced it is buying Myovant Sciences (MYOV) in a $2.9 billion deal. This is why.
Myovant Sciences Cancels Second Quarter Earnings Conference Call
GlobeNewsWire
24 окт 2022 г. в 16:30
BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd.
MYOV Stock Pops as Sumitomo Agrees to Buy Myovant Sciences
InvestorPlace
24 окт 2022 г. в 11:23
Today's market-moving news in the drugmaker sector is that Sumitomo Pharma and a subsidiary have agreed to buy out the remainder of Myovant Sciences (NYSE: MYOV ) that they don't already own. Furthermore, they raised their offer to make this purchase.